This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barbet, J. Search for Related Content PubMed PubMed Citation Articles by Barbet, J. Related Collections Thyroid Endocrine Oncology

Prognostic Impact of Serum Calcitonin and Carcinoembryonic Antigen Doubling-Times in Patients with Medullary Thyroid Carcinoma

Institut National de la Santé et de la Recherche Médicale, Unité 601 (J.B., F.K.-B., J.-F.C.), F-44000 Nantes, France; Université de Nantes (J.B., F.K.-B., J.-F.C.), F-44000 Nantes, France; and René Gauducheau Cancer Center (L.C.), F-44805 Nantes-St. Herblain, France

Address all correspondence and requests for reprints to: Jacques Barbet, Département de Recherche en Cancérologie, Institut National de la Santé et de la Recherche Médicale, Unité 601, Institut de Biologie, 9 quai Moncousu, 44093 Nantes cedex 1, France. E-mail: Jacques.Barbet{at}nantes.inserm.fr.

Context: After unsuccessful surgery, medullary thyroid carcinoma (MTC) may be fatal or remain stable for decades, and precise survival predictors are needed.

Objective: This study assesses the prognostic value of calcitonin and carcinoembryonic antigen (CEA) doubling-times (DT).

Design: This is a retrospective study on 65 MTC patients from 2.9–29.5 yr after surgery.

Setting: Data registered in the database of the French Neuroendocrine Tumor Group were analyzed anonymously.

Patients: All patients had abnormal calcitonin levels after total thyroidectomy and bilateral lymph node dissection.

Intervention: Calcitonin and CEA serum levels were measured during routine disease follow-up.

Main Outcome Measure: To assess DT as prognostic factors, a patient population was extracted from the database.

Results: When calcitonin DT was less than 6 months, 5- and 10-yr survivals were three of 12 (25%) and one of 12 (8%), respectively; when between 6 months and 2 yr, 5- and 10-yr survivals were 11 of 12 (92%) and three of eight (37%), whereas all 41 patients with calcitonin DT greater than 2 yr were alive at the end of the study. Tumor-Node-Metastasis (TNM) stage, European Organization for Research and Treatment of Cancer (EORTC) score, and calcitonin DT were significant predictors of survival by univariate analysis, but only calcitonin DT remained an independent predictor of survival by multivariate analysis (P = 0.002) with a proportion of variance explained (PVE) of 37.4%. Calcitonin DT was a better predictor than CEA (PVE 63.3% and 47.0%, respectively). Calcitonin DT calculated using only the first four measurements was also an independent predictor of survival (P < 0.000001; PVE 40.4%).

Conclusion: Calcitonin DT may be superior to initial clinical staging and among the most powerful prognostic indicators in MTC.

This article has been cited by other articles:

				M. Wuttke, C. Papewalis, Y. Meyer, C. Kessler, B. Jacobs, H. S. Willenberg, S. Schinner, C. Kouatchoua, T. Baehring, W. A. Scherbaum, et al. Amino Acid-Modified Calcitonin Immunization Induces Tumor Epitope-Specific Immunity in a Transgenic Mouse Model for Medullary Thyroid Carcinoma Endocrinology, November 1, 2008; 149(11): 5627 - 5634. [Abstract] [Full Text] [PDF]

				C. Papewalis, M. Wuttke, J. Seissler, Y. Meyer, C. Kessler, B. Jacobs, E. Ullrich, H. S. Willenberg, S. Schinner, T. Baehring, et al. Dendritic Cell Vaccination with Xenogenic Polypeptide Hormone Induces Tumor Rejection in Neuroendocrine Cancer Clin. Cancer Res., July 1, 2008; 14(13): 4298 - 4305. [Abstract] [Full Text] [PDF]

				A. Machens, S. Hauptmann, and H. Dralle Medullary Thyroid Cancer Responsiveness to Pentagastrin Stimulation: An Early Surrogate Parameter of Tumor Dissemination? J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2234 - 2238. [Abstract] [Full Text] [PDF]

				A. Laure Giraudet, A. Al Ghulzan, A. Auperin, S. Leboulleux, A. Chehboun, F. Troalen, C. Dromain, J. Lumbroso, E. Baudin, and M. Schlumberger Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times Eur. J. Endocrinol., February 1, 2008; 158(2): 239 - 246. [Abstract] [Full Text] [PDF]

				A. Oudoux, P.-Y. Salaun, C. Bournaud, L. Campion, C. Ansquer, C. Rousseau, S. Bardet, F. Borson-Chazot, J.-P. Vuillez, A. Murat, et al. Sensitivity and Prognostic Value of Positron Emission Tomography with F-18-Fluorodeoxyglucose and Sensitivity of Immunoscintigraphy in Patients with Medullary Thyroid Carcinoma Treated with Anticarcinoembryonic Antigen-Targeted Radioimmunotherapy J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4590 - 4597. [Abstract] [Full Text] [PDF]

				F. Iten, B. Muller, C. Schindler, C. Rochlitz, D. Oertli, H. R. Macke, J. Muller-Brand, and M. A. Walter Response to [90Yttrium-DOTA]-TOC Treatment is Associated with Long-term Survival Benefit in Metastasized Medullary Thyroid Cancer: A Phase II Clinical Trial Clin. Cancer Res., November 15, 2007; 13(22): 6696 - 6702. [Abstract] [Full Text] [PDF]

				N. Aide and S. Bardet Would Patient Selection Based on Both Calcitonin Blood Level and Doubling Time Improve 18F-FDG PET Sensitivity in Restaging of Medullary Thyroid Cancer? J. Nucl. Med., September 1, 2007; 48(9): 1574 - 1574. [Full Text] [PDF]

				H. Schoder and R. M. Tuttle Reply: Would Patient Selection Based on Both Calcitonin Blood Level and Doubling Time Improve 18F-FDG PET Sensitivity in Restaging of Medullary Thyroid Cancer? J. Nucl. Med., September 1, 2007; 48(9): 1574 - 1575. [Full Text] [PDF]

				B. H.-H. Lang, C.-Y. Lo, W.-F. Chan, K.-Y. Lam, and K.-Y. Wan Staging systems for follicular thyroid carcinoma: application to 171 consecutive patients treated in a tertiary referral centre Endocr. Relat. Cancer, March 1, 2007; 14(1): 29 - 42. [Abstract] [Full Text] [PDF]

				A. Machens, J. Ukkat, S. Hauptmann, and H. Dralle Abnormal Carcinoembryonic Antigen Levels and Medullary Thyroid Cancer Progression: A Multivariate Analysis Arch Surg, March 1, 2007; 142(3): 289 - 293. [Abstract] [Full Text] [PDF]

				J. F. Chatal In Reply J. Clin. Oncol., July 10, 2006; 24(20): e38 - e38. [Full Text] [PDF]

				J.-F. Chatal, L. Campion, F. Kraeber-Bodere, S. Bardet, J.-P. Vuillez, B. Charbonnel, V. Rohmer, C.-H. Chang, R. M. Sharkey, D. M. Goldenberg, et al. Survival Improvement in Patients With Medullary Thyroid Carcinoma Who Undergo Pretargeted Anti-Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study With the French Endocrine Tumor Group J. Clin. Oncol., April 10, 2006; 24(11): 1705 - 1711. [Abstract] [Full Text] [PDF]

				D. M. Goldenberg, R. M. Sharkey, G. Paganelli, J. Barbet, and J.-F. Chatal Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy J. Clin. Oncol., February 10, 2006; 24(5): 823 - 834. [Abstract] [Full Text] [PDF]